## Divya Bhagirath

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10428144/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer. Cancer Research, 2018, 78, 1833-1844.	0.4	218
2	<i>BRN4</i> Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with <i>BRN2</i> . Clinical Cancer Research, 2019, 25, 6532-6545.	3.2	46
3	A novel microRNA regulator of prostate cancer epithelial–mesenchymal transition. Cell Death and Differentiation, 2017, 24, 1263-1274.	5.0	32
4	MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer. Oncogene, 2020, 39, 7209-7223.	2.6	28
5	Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients. Scientific Reports, 2021, 11, 8279.	1.6	28
6	Cell type of origin as well as genetic alterations contribute to breast cancer phenotypes. Oncotarget, 2015, 6, 9018-9030.	0.8	19
7	Role of a novel race-related tumor suppressor microRNA located in frequently deleted chromosomal locus 8p21 in prostate cancer progression. Carcinogenesis, 2019, 40, 633-642.	1.3	15
8	MicroRNAs as Regulators of Prostate Cancer Metastasis. Advances in Experimental Medicine and Biology, 2018, 1095, 83-100.	0.8	12
9	MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer. , 2020, 3, 804-818.		6
10	Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients. Journal of Visualized Experiments, 2019, , .	0.2	5
11	Mutant PIK3CA Induces EMT in a Cell Type Specific Manner. PLoS ONE, 2016, 11, e0167064.	1.1	5
12	MicroRNA-4287 is a novel tumor suppressor microRNA controlling epithelial-to mesenchymal transition in prostate cancer. Oncotarget, 2020, 11, 4681-4692.	0.8	5
13	Coping with chemoresistance in prostate cancer—co-targeting of adipose stromal cells?. Translational Andrology and Urology, 2019, 8, S250-S253.	0.6	3